Incyte Corporation is a global biopharmaceutical company focused on discovery, development, and commercialization of proprietary therapeutics in three areas: Hematology, Oncology, and Inflammation and Autoimmunity (IAI). Its approved products include JAKAFI (ruxolitinib) for MF, PV, and GVHD; ICLUSIG (ponatinib) for CML and Ph+ ALL; MONJUVI/MINJUVI (tafasitamab) for DLBCL and FL; NIKTIMVO (axatilimab-csfr) for chronic GVHD; PEMAZYRE (pemigatinib) for cholangiocarcinoma; and ZYNYZ (retifanlimab-dlwr). Headquartered in Wilmington, Delaware, with European, Japanese, and Canadian offices.
expected 2026-11-30
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-10 | 2025-12-31 | 0000879169-26-000010 | EDGAR | 78K words |
| 2025-02-10 | 2024-12-31 | 0001628280-25-004633 | EDGAR | 82K words |
| 2024-02-13 | 2023-12-31 | 0000879169-24-000045 | EDGAR | 78K words |
| 2023-02-07 | 2022-12-31 | 0000879169-23-000008 | EDGAR | 83K words |
| 2022-02-08 | 2021-12-31 | 0001558370-22-000902 | EDGAR | 86K words |
| 2021-02-09 | 2020-12-31 | 0001558370-21-000825 | EDGAR | 87K words |
| 2020-02-13 | 2019-12-31 | 0001558370-20-000774 | EDGAR | 87K words |
| 2019-02-14 | 2018-12-31 | 0001558370-19-000682 | EDGAR | 90K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-10-29 | 2026-09-30 | 0000879169-26-000066 | EDGAR | 49K words |
| 2026-07-28 | 2026-06-30 | 0000879169-26-000056 | EDGAR | 48K words |
| 2025-10-28 | 2025-09-30 | 0000879169-25-000118 | EDGAR | 51K words |
| 2025-07-29 | 2025-06-30 | 0000879169-25-000103 | EDGAR | 54K words |
| 2025-04-29 | 2025-03-31 | 0000879169-25-000056 | EDGAR | 50K words |
| 2024-10-29 | 2024-09-30 | 0000879169-24-000172 | EDGAR | 53K words |
| 2024-07-30 | 2024-06-30 | 0000879169-24-000149 | EDGAR | 52K words |
| 2024-04-30 | 2024-03-31 | 0000879169-24-000077 | EDGAR | 48K words |
| 2023-10-31 | 2023-09-30 | 0000879169-23-000041 | EDGAR | 55K words |
| 2023-08-01 | 2023-06-30 | 0000879169-23-000025 | EDGAR | 55K words |
| 2023-05-02 | 2023-03-31 | 0000879169-23-000016 | EDGAR | 51K words |
| 2022-11-01 | 2022-09-30 | 0000879169-22-000010 | EDGAR | 55K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-11-13 | 0000879169-26-000068 | EDGAR | 1K words |
| 2026-10-29 | 0000879169-26-000063 | EDGAR | 10K words |
| 2026-08-31 | 0000879169-26-000058 | EDGAR | 1K words |
| 2026-07-28 | 0000879169-26-000053 | EDGAR | 10K words |
| 2026-03-30 | 0000879169-26-000018 | EDGAR | 1K words |
| 2026-03-26 | 0000879169-26-000016 | EDGAR | 1K words |
| 2026-03-06 | 0000879169-26-000013 | EDGAR | 1K words |
| 2026-02-10 | 0000879169-26-000006 | EDGAR | 9K words |
| 2025-12-12 | 0000879169-25-000122 | EDGAR | 0K words |
| 2025-10-28 | 0000879169-25-000115 | EDGAR | 8K words |
109 total filings indexed. 79 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000879169 |
| Ticker | INCY |
| Exchange | Nasdaq |
| SIC | 8731: Services-Commercial Physical & Biological Research |
| Incorporated | DE |
| Headquarters | Wilmington, Delaware |
| Website | https://www.incyte.com |
| Listed | 1993-11-03 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/INCY (~200 tokens, structured JSON with cryptographic provenance)